Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. - Wikidata - awgldk - TriplyDB

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.

http://www.wikidata.org/entity/Q40058838

about

P2Y12-ADP receptor antagonists: Days of future and past State of the art: Oral antiplatelet therapy Type 2 Diabetes and ADP Receptor Blocker Therapy Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar The prognostic impact of high on-treatment platelet reactivity with aspirin or ADP receptor antagonists: systematic review and meta-analysis Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice Recent advances in treatment of acute coronary syndromes Treatment and prevention of gastrointestinal bleeding in patients receiving antiplatelet therapy High-maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy The risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease.Case scenario: a patient on dual antiplatelet therapy with an intracranial hemorrhage after percutaneous coronary intervention Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry.Recent advances in antithrombotic therapy after acute coronary syndrome.Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus.Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison.Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy.Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel.Antithrombotic therapy for long-term secondary prevention of acute coronary syndrome in high-risk patients.Optimal oral antithrombotic regimes for patients with acute coronary syndrome: a network meta-analysis Impact of Human Development Index on the profile and outcomes of patients with acute coronary syndrome.Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study.Importance of frailty in patients with cardiovascular disease.Harmonizing Optimal Strategy for Treatment of coronary artery diseases--comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial.Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes.Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.Causes of late mortality with dual antiplatelet therapy after coronary stents.Novel antiplatelet agent use for acute coronary syndrome in the emergency department: a review State of the art in platelet function testing.Doubly blind: a systematic review of gender in randomised controlled trials.Systematic review and meta-analysis of optimal P2Y12 blockade in dual antiplatelet therapy for patients with diabetes with acute coronary syndrome Switching between thienopyridines in patients with acute myocardial infarction and quality of care.Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes Outcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients With Non-ST-Segment Elevation Myocardial Infarction Discharged Without In-hospital Revascularization The perioperative management of treatment with anticoagulants and platelet aggregation inhibitors.New antiplatelet agents for cardiovascular disease.Bleeding events and maintenance dose of prasugrel: BLESS pilot study.

P2860

Q26745619-6549EA54-6C0C-40DF-B09E-FC048C9E8396 Q26746161-B52D28F7-69EC-40EE-AAE1-DD8E3B742CED Q26772996-59FCF99B-CAB6-480D-9682-B8792926214A Q26782970-BB5BDE32-254F-48FB-8473-423531CB44BD Q26801144-8CC7B64F-2F98-4CAC-B339-4B1D6E20DEA6 Q26824694-A81C68EA-F385-49BE-8376-9FC1A446D47A Q26825230-EA94447A-5813-4476-8CAF-6AF3EA813B91 Q26862897-00F933EC-59CB-499D-8038-D5D7EEEE874D Q26866350-B40D5140-2EA9-4B03-A5BC-8A1113D8CD56 Q26996325-040D2E21-B6FA-495E-920C-9703E232E901 Q26998331-05B4745C-1E26-49AB-9172-72A0DBDF7E95 Q30234909-D03EA0C4-DF2A-493E-B3E5-B57F7D7BB275 Q30371026-E37914BD-2DE0-4130-8A5E-F26D9319A938 Q30800602-C4B73027-2A48-4B9F-9D11-BA9BA4F4AA28 Q33590548-1115C170-C8C9-47CB-97BE-06DC97B17038 Q33706621-ACDB8F9C-5D67-4129-852B-1F603A1D77C1 Q34043989-E4833F3C-9995-4667-BC73-2C05998A0772 Q34371979-87B4F2C1-8C16-49AB-B639-430041E20BF9 Q34456208-92450A49-A0FC-4F02-8268-F6CCDF46D3C1 Q35048557-6AD5DE36-0C7B-4CC0-B684-5C3652A5767B Q35089550-B95FE59F-4113-4931-A9C3-A343E20C4BB0 Q35111496-660BFB03-996B-4ADE-8117-AF7A5114B04E Q35116512-3CD1D5A6-312A-49B0-9EBE-2ED463793D64 Q35135852-734AED6C-C526-4135-827D-6D252C2D6DBB Q35204942-4B4C2EB7-A101-4413-8765-9AFDA35D99E2 Q36047672-D9E3F8F2-641E-4CEE-83E8-ED2CAAA13833 Q36060147-799706F0-1D26-48B0-AC6A-AC110C9FE7C7 Q36141930-316F6E0B-E284-4B3E-AAD7-1378DA99224D Q36484993-9940119C-5EA2-486B-8960-FD576E20F5A3 Q36573521-CDD665D7-32FF-49E6-98D1-7DA473CDF6DA Q36676694-C219A3B6-AD7E-402B-B3B9-5416CA694FEB Q36802971-5B5E9248-E8A4-4E7E-8744-E7B0EDACC7C5 Q36805845-6F568936-8177-4729-8E0F-0C1F90E00404 Q36841959-9D4C0D19-28BA-44DB-A9C2-47A251F68600 Q36947677-847C93BB-4B58-4BA4-AE0B-EF27ABD0E75F Q37022618-B8D312E5-B5CD-4A3B-BA6A-EC5F88B87E03 Q37090758-33BD7B4E-AC01-466E-99AC-B7F2944E83CB Q37194881-B3A91A80-6897-4297-8D6E-690A4CB1EC70 Q37304566-5BE91E85-D9DD-4894-B340-5DB52753537C Q37390051-2A7CCE92-ADCD-4D3E-87A5-A90A85DFBF96

P2860

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.

http://www.wikidata.org/entity/Q40058838

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.

@en

type

label

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.

@en

prefLabel

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.

@en

P1433

Q40058838-F46F82A8-65D1-400B-8B62-D8426E5693E9

P1476

Q40058838-2FBA280D-1DA5-4983-B765-1E360787E606

P2093

Q40058838-037F0C9A-F396-4097-B419-415F91423A81

Q40058838-0FAAF656-D249-4377-9398-B5F38BFF4405

Q40058838-19576563-F396-4A74-832E-F2B4505ED7CD

Q40058838-1BB6688B-996B-48E1-8AD0-51EF0F5C6EE8

Q40058838-3674FC97-922F-4BF8-A869-C9E82F85BF99

Q40058838-390A9F99-A901-41FE-A5F9-C491C6FA65D3

Q40058838-3F3577E6-7E21-457D-B43F-B9106D32A8A9

Q40058838-4C85BE62-62B6-465E-BD82-42888BF20AF7

Q40058838-4EBC5F34-99DE-4B6A-ADDD-37D050F10B3B

Q40058838-5132CFF6-F279-4FA2-8DB3-4E74B3C719A7

P304

Q40058838-44E0AE3E-7938-499E-B983-43C9854E4C74

P31

Q40058838-08ACF81D-4F40-49B4-94C8-AC8D96D33069

P356

Q40058838-3E3917ED-D224-43DE-B3C3-7275C10310EB

P407

Q40058838-24F0D6E1-BCB0-4417-BF1C-7C62F8392682

P433

Q40058838-E0B11A33-8B61-41DB-92D1-9157BB55D0AB

P478

Q40058838-E09A7B98-53CB-4058-A8C8-B10AC2D8AEF5

P50

Q40058838-18680FFA-CDFD-4FBF-921D-4452DE900CE9

Q40058838-694F0B1A-D8C6-4FB6-AD8E-C5D1C2A406BB

Q40058838-75CF1185-E65B-439D-8C8C-6565E0F6CBF7

Q40058838-8C3408BA-CAF0-47DD-BB95-99732023ECDB

Q40058838-A278ABC3-B2B7-4DC1-8A06-4394966C34E0

Q40058838-B36FF8FE-1CB0-4588-AB1D-FBECC80EFF06

P577

Q40058838-924CAD80-4D94-41D3-8863-FF0F08C43023

P698

Q40058838-2DC99DBF-97F9-44E6-AEC5-7F6901C393DA

P921

Q40058838-09D092A7-E623-45C6-843B-EA2255C68197

Q40058838-EF0B1210-E0CE-490B-B751-C366CA6AECAA

P356

P1433

The New England Journal of Medicine

P1476

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.

@en

P2093

Alexander Parkhomenko

http://www.w3.org/2001/XMLSchema#string

Ali Oto

http://www.w3.org/2001/XMLSchema#string

Anthony J Dalby

http://www.w3.org/2001/XMLSchema#string

Assen R Goudev

http://www.w3.org/2001/XMLSchema#string

Bela Merkely

http://www.w3.org/2001/XMLSchema#string

Christian Hamm

http://www.w3.org/2001/XMLSchema#string

Chuen-Den Tseng

http://www.w3.org/2001/XMLSchema#string

Darren K McGuire

http://www.w3.org/2001/XMLSchema#string

Deepak L Bhatt

http://www.w3.org/2001/XMLSchema#string

Diego Ardissino

http://www.w3.org/2001/XMLSchema#string

P304

1297-1309

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1205512

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

367

http://www.w3.org/2001/XMLSchema#string

P50

Dorairaj Prabhakaran

Paul W. Armstrong

Judith S Hochman

Erik Magnus Ohman

Yuliya Lokhnygina

P577

2012-08-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22920930

http://www.w3.org/2001/XMLSchema#string

P921

revascularization